EA201891443A1 - Фармацевтические композиции, содержащие фениламинопиримидиновое производное - Google Patents

Фармацевтические композиции, содержащие фениламинопиримидиновое производное

Info

Publication number
EA201891443A1
EA201891443A1 EA201891443A EA201891443A EA201891443A1 EA 201891443 A1 EA201891443 A1 EA 201891443A1 EA 201891443 A EA201891443 A EA 201891443A EA 201891443 A EA201891443 A EA 201891443A EA 201891443 A1 EA201891443 A1 EA 201891443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
compositions containing
phenylaminopyrimidine derivative
compositions
malignant tumor
Prior art date
Application number
EA201891443A
Other languages
English (en)
Other versions
EA036513B1 (ru
Inventor
Дурга Махесвари Парватанени
Митрабхану Моханти
Венката Сатьянараяна Аппадведула
Кали Сатья Бхуджанга Рао Адибхатла
Венкайах Човдари Наннапанени
Original Assignee
Натко Фарма Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Натко Фарма Лтд filed Critical Натко Фарма Лтд
Publication of EA201891443A1 publication Critical patent/EA201891443A1/ru
Publication of EA036513B1 publication Critical patent/EA036513B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Пероральная фармацевтическая композиция, включающая эффективное количество NRC-AN-019, включая его фармацевтически приемлемые соли и полиморфы, путем диспергирования в полимерной системе с наименьшим размером частиц для повышения пероральной биодоступности. Изобретение также относится к способам получения таких композиций и к применению этих композиций для лечения хронического миелоидного лейкоза и других опухолей, таких как злокачественная опухоль головы и шеи, злокачественная опухоль предстательной железы и тому подобное.
EA201891443A 2015-12-18 2016-01-30 Фармацевтические композиции, содержащие фениламинопиримидиновое производное EA036513B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (en) 2015-12-18 2016-01-30 Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Publications (2)

Publication Number Publication Date
EA201891443A1 true EA201891443A1 (ru) 2019-01-31
EA036513B1 EA036513B1 (ru) 2020-11-18

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891443A EA036513B1 (ru) 2015-12-18 2016-01-30 Фармацевтические композиции, содержащие фениламинопиримидиновое производное

Country Status (32)

Country Link
US (1) US10383872B2 (ru)
EP (1) EP3389633B1 (ru)
JP (2) JP6896738B2 (ru)
KR (1) KR20180102584A (ru)
CN (1) CN108495620B (ru)
AU (1) AU2016373574B2 (ru)
BR (1) BR112018012458A2 (ru)
CA (1) CA3008634A1 (ru)
CL (1) CL2018001590A1 (ru)
CO (1) CO2018007112A2 (ru)
CY (1) CY1124580T1 (ru)
DK (1) DK3389633T3 (ru)
EA (1) EA036513B1 (ru)
ES (1) ES2881883T3 (ru)
GB (1) GB2564262A (ru)
GE (1) GEP20207176B (ru)
HK (1) HK1254573A1 (ru)
HR (1) HRP20211590T1 (ru)
HU (1) HUE056269T2 (ru)
IL (1) IL260085B (ru)
LT (1) LT3389633T (ru)
MA (1) MA44079B1 (ru)
MX (1) MX2018007281A (ru)
PH (1) PH12018501292A1 (ru)
PL (1) PL3389633T3 (ru)
PT (1) PT3389633T (ru)
RS (1) RS62422B1 (ru)
SG (1) SG11201805142RA (ru)
SI (1) SI3389633T1 (ru)
UA (1) UA122592C2 (ru)
WO (1) WO2017103941A1 (ru)
ZA (1) ZA201804203B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3793527A1 (en) * 2018-05-14 2021-03-24 Capsugel Belgium NV Solid dosage forms with high active agent loading
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition

Also Published As

Publication number Publication date
GB201811142D0 (en) 2018-08-22
BR112018012458A2 (pt) 2018-12-18
MA44079B1 (fr) 2021-10-29
EP3389633A4 (en) 2019-08-07
EP3389633B1 (en) 2021-07-14
US10383872B2 (en) 2019-08-20
ES2881883T3 (es) 2021-11-30
DK3389633T3 (da) 2021-08-30
PT3389633T (pt) 2021-08-05
GEP20207176B (en) 2020-11-10
JP6896738B2 (ja) 2021-06-30
JP2021059551A (ja) 2021-04-15
UA122592C2 (uk) 2020-12-10
EP3389633A1 (en) 2018-10-24
CN108495620B (zh) 2021-09-03
CO2018007112A2 (es) 2018-07-19
SI3389633T1 (sl) 2021-11-30
PH12018501292A1 (en) 2019-02-04
GEAP201614833A (ru) 2020-06-25
AU2016373574B2 (en) 2021-10-14
CA3008634A1 (en) 2017-06-22
JP2018538325A (ja) 2018-12-27
IL260085A (en) 2018-07-31
PL3389633T3 (pl) 2021-12-13
MA44079A (fr) 2021-04-21
SG11201805142RA (en) 2018-07-30
WO2017103941A1 (en) 2017-06-22
ZA201804203B (en) 2020-08-26
RS62422B1 (sr) 2021-10-29
HUE056269T2 (hu) 2022-02-28
US20190015412A1 (en) 2019-01-17
MX2018007281A (es) 2018-11-29
HRP20211590T1 (hr) 2022-01-07
CN108495620A (zh) 2018-09-04
GB2564262A (en) 2019-01-09
KR20180102584A (ko) 2018-09-17
CY1124580T1 (el) 2022-07-22
LT3389633T (lt) 2021-09-10
IL260085B (en) 2021-09-30
CL2018001590A1 (es) 2018-11-30
EA036513B1 (ru) 2020-11-18
HK1254573A1 (zh) 2019-07-19
AU2016373574A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
EA201891443A1 (ru) Фармацевтические композиции, содержащие фениламинопиримидиновое производное
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
PH12019501896A1 (en) Therapeutic dendrimers
EA033689B9 (ru) Ингибиторы g12c kras
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201691940A1 (ru) Новые соединения
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
PH12016502354A1 (en) Pharmaceutical composition
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
UA114944C2 (uk) Піридинільні і конденсовані піридинільні похідні триазолону
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA201691342A1 (ru) Пиразолоновые соединения и их применение
MD20160016A2 (ru) Новые индолизиновые соединения, способ их получения ифармацевтические композиции, их содержащие
BR112014016635B8 (pt) composto, composição, e, uso de um composto
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
TR201819805T4 (tr) Flavaglin türevleri̇.
MX369473B (es) Derivado de indolona sustituido por pirrol, método de preparación del mismo, composición que comprende el mismo y uso del mismo.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.